Table 1
Cumulative survival rates for non-alcoholic fatty liver disease patients at 1, 5, 10, and 15 years, categorized by the specific high-sensitivity cardiac troponin test used to identify myocardial injury (unadjusted).
| hs-cTn ASSAY/TIME POINT* | WITHOUT MYOCARDIAL INJURY | MYOCARDIAL INJURY |
|---|---|---|
| Any hs-cTn assay (weighted) | 38897184 | 2931677 |
| 1 year, % | 99.735 | 96.943 |
| 5 years, % | 97.212 | 74.604 |
| 10 years, % | 91.017 | 52.734 |
| 15 years, % | 83.871 | 32.777 |
| hs-cTn T (weighted) | 39241902 | 2586958 |
| 1 year, % | 99.738 | 96.535 |
| 5 years, % | 97.190 | 71.937 |
| 10 years, % | 90.942 | 48.774 |
| 15 years, % | 83.590 | 30.238 |
| hs-cTn I Abbott (weighted) | 41342518 | 486343 |
| 1 year, % | 99.637 | 91.275 |
| 5 years, % | 95.869 | 75.136 |
| 10 years, % | 88.664 | 60.257 |
| 15 years, % | 80.804 | 36.623 |
| hs-cTn I Siemens (weighted) | 41223397 | 605463 |
| 1 year, % | 99.604 | 95.181 |
| 5 years, % | 95.857 | 80.008 |
| 10 years, % | 88.722 | 61.890 |
| 15 years, % | 80.922 | 37.250 |
| hs-cTn I Ortho (weighted) | 41342518 | 486343 |
| 1 year, % | 99.637 | 91.275 |
| 5 years, % | 95.869 | 75.136 |
| 10 years, % | 88.664 | 60.257 |
| 15 years, % | 80.804 | 36.623 |
[i] *All statistical analyses and derived estimates utilize weighted data records
Figure 1
Kaplan–Meier survival curve for patients with non-alcoholic fatty liver disease using any high-sensitivity cardiac troponin assay to define myocardial injury. (A) all-cause mortality; (B) cardiovascular disease mortality.
Table 2
Adjusted hazard ratios for myocardial injury in non-alcoholic fatty liver disease patients, categorized by high-sensitivity cardiac troponin assay type (Cox proportional hazards regression model).
| OUTCOME | hs-cTn ASSAY | aHR (95% CI)* | P-VALUE |
|---|---|---|---|
| All-cause mortality | |||
| Any hs-cTn assay | 1.785 (1.494–2.134) | <0.00001 | |
| hs-cTn T | 1.751 (1.453–2.111) | <0.00001 | |
| hs-cTn I Abbott | 1.749 (1.180–2.592) | 0.00535 | |
| hs-cTn I Ortho | 1.809 (1.313–2.493) | 0.00029 | |
| hs-cTn I Siemens | 2.235 (1.642–3.042) | <0.00001 | |
| Cardiovascular mortality | |||
| Any hs-cTn assay | 2.155 (1.606–2.893) | <0.00001 | |
| hs-cTn T | 2.230 (1.645–3.023) | <0.00001 | |
| hs-cTn I Abbott | 2.811 (1.579–5.004) | 0.00044 | |
| hs-cTn I Ortho | 2.409 (1.485–3.909) | 0.00037 | |
| hs-cTn I Siemens | 2.557 (1.552–4.213) | 0.00023 | |
[i] The following variables were adjusted: age, sex, race/ethnicity, BMI, education level, marital status, history of malignancy, cardiovascular disease, diabetes mellitus, hypertension, smoking history, statins use, antihypertensive drugs, antidiabetic drugs, antiplatelet drugs, glucose, total cholesterol, diastolic blood pressure, systolic blood pressure, HbA1c (%), ALT; HDL-C; C reactive protein, blood urea nitrogen, uric acid, and sarcopenia; aHR, adjusted hazard ratio.
*Reference group: non-alcoholic fatty liver disease patients without myocardial injury.
Figure 2
Kaplan–Meier survival curve for patients with non-alcoholic fatty liver disease without known cardiovascular disease using any high-sensitivity cardiac troponin assay to define myocardial injury. (A) all-cause mortality; (B) cardiovascular disease mortality.
Table 3
Adjusted hazard ratios for myocardial injury in non-alcoholic fatty liver disease patients without known cardiovascular disease, categorized by high-sensitivity cardiac troponin assay type (Cox proportional hazards regression model).
| OUTCOME | hs-cTn ASSAY | aHR (95%CI) | P-VALUE |
|---|---|---|---|
| All-cause mortality | |||
| Any hs-cTn assay | 1.771 (1.423, 2.204) | <0.00001 | |
| hs-cTn T | 1.706 (1.354, 2.149) | <0.00001 | |
| hs-cTn I Abbott | 1.750 (1.033, 2.976) | 0.03759 | |
| hs-cTn I Ortho | 1.619 (1.025, 2.557) | 0.03870 | |
| hs-cTn I Siemens | 2.210 (1.473, 3.316) | 0.00013 | |
| Cardiovascular mortality | |||
| Any hs-cTn assay | 2.203 (1.517, 3.198) | 0.00003 | |
| hs-cTn T | 2.271 (1.547, 3.335) | 0.00003 | |
| hs-cTn I Abbott | 1.771 (0.682, 4.601) | 0.24071 | |
| hs-cTn I Ortho | 2.142 (1.028, 4.463) | 0.04195 | |
| hs-cTn I Siemens | 2.639 (1.285, 5.420) | 0.00821 | |
[i] The following variables were adjusted: age, sex, race/ethnicity, BMI, education level, marital status, history of malignancy, diabetes mellitus, hypertension, smoking history, statins use, antihypertensive drugs, antidiabetic drugs, antiplatelet drugs, glucose, total cholesterol, diastolic blood pressure, systolic blood pressure, HbA1c (%), ALT; HDL-C; C reactive protein, blood urea nitrogen, uric acid, and sarcopenia; aHR, adjusted hazard ratio.
*Reference group: non-alcoholic fatty liver disease patients without myocardial injury.
Table 4
Adjusted hazard ratios for myocardial injury in non-alcoholic fatty liver disease patients after excluding participants who died within the first two years of follow-up, categorized by high-sensitivity cardiac troponin assay type (Cox proportional hazards regression model).
| OUTCOME | hs-cTn ASSAY | aHR (95%CI) | P-VALUE |
|---|---|---|---|
| All-cause mortality | |||
| Any hs-cTn assay | 1.746 (1.450, 2.101) | <0.00001 | |
| hs-cTn T | 1.679 (1.381, 2.042) | <0.00001 | |
| hs-cTn I Abbott | 1.724 (1.132, 2.627) | 0.01120 | |
| hs-cTn I Ortho | 1.947 (1.392, 2.722) | 0.00010 | |
| hs-cTn I Siemens | 2.173 (1.563, 3.021) | <0.00001 | |
| Cardiovascular mortality | |||
| Any hs-cTn assay | 2.092 (1.540, 2.843) | <0.00001 | |
| hs-cTn T | 2.147 (1.562, 2.951) | <0.00001 | |
| hs-cTn I Abbott | 2.529 (1.340, 4.773) | 0.00418 | |
| hs-cTn I Ortho | 2.257 (1.332, 3.822) | 0.00247 | |
| hs-cTn I Siemens | 2.329 (1.354, 4.009) | 0.00227 | |
[i] The following variables were adjusted: age, sex, race/ethnicity, BMI, education level, marital status, history of malignancy, diabetes mellitus, hypertension, smoking history, statins use, antihypertensive drugs, antidiabetic drugs, antiplatelet drugs, glucose, total cholesterol, diastolic blood pressure, systolic blood pressure, HbA1c (%), ALT; HDL-C; C reactive protein, blood urea nitrogen, uric acid, and sarcopenia; aHR, adjusted hazard ratio.
*Reference group: non-alcoholic fatty liver disease patients without myocardial injury.